1st Multi-stakeholder Symposium on Improving Patient Access to Rare Disease Therapies
24 - 25 February 2016
The Multi-Stakeholder Symposium on Improving Patient Access to Rare Disease Therapies aimed at addressing a crucial bottleneck in making orphan medicinal products (OMP) accessible across Europe.
A unique combination of nearly 300 patient advocates, academics, policymakers, industry representatives, payers and HTA bodies came together to discuss the current state of play and how to shape a more effective way to address value determination, appraisal, pricing and reimbursement of orphan medicines, all with the aim of improving patients’ access to rare disease therapies throughout Europe.
By bringing together such a varied range of stakeholders, the Symposium created an opportunity for exchange to reach an understanding of the varied perspectives on issues and challenges surrounding patient access. Participants discussed various methods of appraisal, value determination and reimbursement and also took part in pricing simulation exercises.
Speakers included European Commissioner for Health Vytenis Andriukaitis and Members of the European Parliament Philippe De Backer and Françoise Grossetête.
Date: Thursday 4th February 2016, from 15.00 to 16.00 CET Moderator: Julia Chamova from EUnetHTA Co-presented by Conor Teljeur from EUnetHTA & François Houÿez, Treatment Information and Access Director at EURORDIS.